Shares of Biocon soared over 7% in early trade on Wednesday as investors cheered the biopharmaceutical company’s fourth-quarter earnings that topped Street estimates. The Kiran Mazumdar-Shaw-led company also announced a final dividend of ₹1.50 per equity share of face value of ₹5 each for the financial year ended March 31, 2023. In the past 12 months, the Bengaluru-based company declared an equity dividend amounting to ₹0.50 per share, while it paid 18 dividends since its listing in 2004.

Continuing its gaining streak for the second day, Biocon shares opened 6.2% higher at ₹257.35 against the previous closing price of ₹242.25 on the BSE. In the first two-hour of trade so far, the pharma heavyweight rose as much as 7.1% to hit a high of ₹259.50, while the market capitalisation climbed to ₹29,787 crore.

At the current levels, Biocon shares trade 25% lower than its 52-week high of ₹344 touched on June 10, 2022, while it is up 35% against its 52-week low of ₹191.60 hit on March 21, 2023. The midcap stock has delivered a negative return of 25% to its shareholders in the past 12 months, while it has lost 9% in the six-month period. In the past month, the counter has risen 10%, while it gained nearly 1% in a week.

In a late evening filing on Tuesday, Biocon said that it posted 31% growth in profit after tax (PAT) at ₹313 crore as against ₹239 crore in the same quarter last year. The revenues for this quarter jumped 57% to ₹3,774 crore compared with ₹2,409 crore in Q4 FY22. EBITDA for the quarter increased 75% to ₹1,152 crore, representing an EBITDA margin of 29% versus 27% in the same period last year.

For the entire year, net profit, before exceptional items, stood at ₹787 crore versus ₹722 crore in FY22. The revenues were up 38% YoY at ₹11,550 crore, while EBITDA for the year was up 32% YoY at ₹2,888 crore, with the margin at 25%.

“FY23 has been a transformational year led by the acquisition of our partnered biosimilars business from Viatris, which has significantly contributed to Biocon’s robust consolidated financials. Revenues grew 38% to ₹11,550 crore, EBITDA was at ₹2,888 Crore, reporting a 32% growth. Revenue growth was led by Biosimilars at 61%, Research Services at 23% and Generics at 13%. R&D Investments have nearly doubled to ₹1,119 crore, as we seek to drive future growth,” says Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics.

(DISCLAIMER: The views and opinions expressed by investment experts on are either their own or of their organisations, but not necessarily that of and its editorial team. Readers are advised to consult certified experts before taking investment decisions.) 

During the year, Serum Institute of Life Sciences (SILS) doubled its investment in Biocon Biologics (BBL) to $300 million as a part of the restructuring of its strategic alliance, through the conversion of its $150 million loan provided to Biocon Pharma into equity in BBL. This is in addition to the $150 million that SILS invested in BBL in November 2022.

The company also plans to raise ₹800 crore ($98 million) from Edelweiss Alternate Asset Advisors Ltd (EAAA) through the issuance of NCDs worth ₹500 crore by Biocon and CCDs worth ₹300 crore by Biocon Biologics.

Follow us on Facebook, X, YouTube, Instagram and WhatsApp to never miss an update from Fortune India. To buy a copy, visit Amazon.